Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Inventory (2016 - 2026)

Anika Therapeutics has reported Inventory over the past 17 years, most recently at $22.8 million for Q1 2026.

  • Quarterly Inventory rose 7.04% to $22.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $22.8 million through Mar 2026, up 7.04% year-over-year, with the annual reading at $18.8 million for FY2025, 21.09% down from the prior year.
  • Inventory was $22.8 million for Q1 2026 at Anika Therapeutics, up from $18.8 million in the prior quarter.
  • Over five years, Inventory peaked at $51.5 million in Q2 2024 and troughed at $16.3 million in Q3 2025.
  • The 5-year median for Inventory is $35.3 million (2022), against an average of $32.9 million.
  • Year-over-year, Inventory rose 20.8% in 2024 and then plummeted 67.12% in 2025.
  • A 5-year view of Inventory shows it stood at $39.8 million in 2022, then crashed by 38.57% to $24.4 million in 2023, then dropped by 2.53% to $23.8 million in 2024, then dropped by 21.09% to $18.8 million in 2025, then rose by 21.56% to $22.8 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Inventory are $22.8 million (Q1 2026), $18.8 million (Q4 2025), and $16.3 million (Q3 2025).